Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Update

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) was the target of a significant drop in short interest in March. As of March 13th, there was short interest totaling 9,838 shares, a drop of 48.4% from the February 26th total of 19,055 shares. Based on an average daily trading volume, of 10,987 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.2% of the company’s stock are short sold.

Institutional Investors Weigh In On Alterity Therapeutics

A number of institutional investors have recently made changes to their positions in ATHE. Twin Lakes Capital Management LLC increased its holdings in shares of Alterity Therapeutics by 2,250.3% during the third quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock valued at $524,000 after acquiring an additional 133,333 shares in the last quarter. Greenleaf Trust raised its holdings in Alterity Therapeutics by 88.2% during the third quarter. Greenleaf Trust now owns 32,000 shares of the company’s stock worth $120,000 after buying an additional 15,000 shares during the last quarter. HB Wealth Management LLC acquired a new position in Alterity Therapeutics during the third quarter worth $220,000. Finally, Citadel Advisors LLC bought a new position in shares of Alterity Therapeutics in the third quarter valued at $83,000. Institutional investors own 2.14% of the company’s stock.

Wall Street Analyst Weigh In

ATHE has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alterity Therapeutics in a research report on Wednesday, January 21st. Canaccord Genuity Group began coverage on shares of Alterity Therapeutics in a research note on Wednesday, December 17th. They issued a “speculative buy” rating on the stock. Finally, Zacks Research raised shares of Alterity Therapeutics to a “hold” rating in a report on Thursday, February 12th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold”.

Alterity Therapeutics Stock Performance

NASDAQ:ATHE traded up $0.06 during trading hours on Friday, hitting $3.22. The company’s stock had a trading volume of 4,335 shares, compared to its average volume of 10,955. Alterity Therapeutics has a twelve month low of $2.52 and a twelve month high of $7.00. The stock has a fifty day simple moving average of $3.41 and a 200-day simple moving average of $3.71.

Alterity Therapeutics (NASDAQ:ATHE) last issued its earnings results on Saturday, January 31st. The company reported ($0.18) earnings per share (EPS) for the quarter. The business had revenue of $0.93 million during the quarter. On average, analysts anticipate that Alterity Therapeutics will post -0.34 EPS for the current fiscal year.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.